$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000158364819000051 Filed on August 09, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$15.13M	$5.332M	$11.69M
YoY Change	81.33%	-54.39%	530.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.840M	$4.190M	$4.780M
YoY Change	1.89%	-12.34%	9.89%
% of Gross Profit
Research & Development	$13.21M	$13.37M	$9.155M
YoY Change	15.88%	46.07%	69.66%
% of Gross Profit
Depreciation & Amortization	$160.0K	$40.00K	$150.0K
YoY Change	23.08%	-73.33%	36.36%
% of Gross Profit
Operating Expenses	$18.05M	$17.56M	$13.93M
YoY Change	11.75%	26.04%	43.0%
Operating Profit	-$2.914M	-$12.23M	-$2.243M
YoY Change	-62.66%	445.25%	-71.58%
Interest Expense	$377.0K	$449.0K	$662.0K
YoY Change	-25.2%	-32.18%
% of Operating Profit
Other Income/Expense, Net	-$55.00K	$23.00K	$1.230M
YoY Change	-104.8%	-98.13%	-189.13%
Pretax Income	-$2.592M	-$11.76M	-$351.0K
YoY Change	-57.87%	3249.86%	-96.21%
Income Tax	$0.00	$0.00	-$148.0K
% Of Pretax Income
Net Earnings	-$2.592M	-$11.76M	-$203.0K
YoY Change	-57.87%	5692.12%	-97.99%
Net Earnings / Revenue	-17.13%	-220.52%	-1.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$52.48K	-$239.0K	-$3.705K
COMMON SHARES
Basic Shares Outstanding	49.39M shares	49.17M shares	53.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.20M	$99.70M	$151.0M
YoY Change	-37.22%	-33.97%	200.2%
Cash & Equivalents	$46.07M	$54.90M	$50.58M
Short-Term Investments	$40.20M	$44.80M	$100.4M
Other Short-Term Assets	$4.800M	$4.600M	$3.100M
YoY Change	14.29%	48.39%	-20.51%
Inventory
Prepaid Expenses
Receivables	$6.952M	$7.174M	$2.559M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$97.97M	$111.5M	$156.6M
YoY Change	-33.28%	-28.82%	52.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.01M	$7.888M	$4.597M
YoY Change	134.86%	71.59%	49.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$700.0K
YoY Change
Other Assets	$7.770M	$11.49M	$129.0K
YoY Change	6321.49%	8806.98%	0.62%
Total Long-Term Assets	$18.78M	$19.38M	$5.426M
YoY Change	290.56%	257.13%	68.86%
TOTAL ASSETS
Total Short-Term Assets	$97.97M	$111.5M	$156.6M
Total Long-Term Assets	$18.78M	$19.38M	$5.426M
Total Assets	$116.8M	$130.8M	$162.0M
YoY Change	-23.02%	-19.25%	52.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.436M	$4.031M	$3.174M
YoY Change	101.86%	27.0%	-31.69%
Accrued Expenses	$7.170M	$8.491M	$4.562M
YoY Change	19.88%	86.12%	-28.17%
Deferred Revenue	$27.24M	$28.41M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$39.85M	$40.93M	$52.33M
YoY Change	-1.84%	-21.79%	46.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.08M	$12.32M	$37.00K
YoY Change	37656.25%	33189.19%	-13.68%
Total Long-Term Liabilities	$12.08M	$12.32M	$37.00K
YoY Change	37656.25%	33189.19%	-13.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.85M	$40.93M	$52.33M
Total Long-Term Liabilities	$12.08M	$12.32M	$37.00K
Total Liabilities	$96.11M	$111.4M	$106.7M
YoY Change	-5.21%	4.36%	10.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$173.4M	-$170.8M	-$129.2M
YoY Change	28.08%	32.18%	7.03%
Common Stock	$194.7M	$193.0M	$187.1M
YoY Change	3.2%	3.14%	41.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.64M	$19.49M	$55.32M
YoY Change
Total Liabilities & Shareholders Equity	$116.8M	$130.8M	$162.0M
YoY Change	-23.02%	-19.25%	52.92%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$2.592M	-$11.76M	-$203.0K
YoY Change	-57.87%	5692.12%	-97.99%
Depreciation, Depletion And Amortization	$160.0K	$40.00K	$150.0K
YoY Change	23.08%	-73.33%	36.36%
Cash From Operating Activities	-$12.65M	-$10.73M	-$8.990M
YoY Change	-11.91%	19.35%	37.88%
INVESTING ACTIVITIES
Capital Expenditures	-$240.0K	-$930.0K	-$400.0K
YoY Change	-25.0%	132.5%	-40.3%
Acquisitions
YoY Change
Other Investing Activities	$4.360M	$13.85M	-$48.37M
YoY Change	-91.88%	-128.63%	-483800.0%
Cash From Investing Activities	$4.120M	$12.92M	-$48.77M
YoY Change	-92.28%	-126.49%	7289.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$50.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	220.0K	280.0K	70.00K
YoY Change	-18.52%	300.0%	-95.21%
NET CHANGE
Cash From Operating Activities	-12.65M	-10.73M	-8.990M
Cash From Investing Activities	4.120M	12.92M	-48.77M
Cash From Financing Activities	220.0K	280.0K	70.00K
Net Change In Cash	-8.310M	2.470M	-57.69M
YoY Change	-121.14%	-104.28%	908.57%
FREE CASH FLOW
Cash From Operating Activities	-$12.65M	-$10.73M	-$8.990M
Capital Expenditures	-$240.0K	-$930.0K	-$400.0K
Free Cash Flow	-$12.41M	-$9.800M	-$8.590M
YoY Change	-11.61%	14.09%	46.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49392706	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	pirs	Accrued License Obligations AccruedLicenseObligations	2523000	USD
CY2019Q2	pirs	Accrued License Obligations AccruedLicenseObligations	2552000	USD
CY2018Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	943000	USD
CY2019Q2	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1409000	USD
	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3350000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4031000	USD
CY2018Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	378000	USD
CY2019Q2	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	317000	USD
	pirs	Additionsto Contractwith Customer Liability AdditionstoContractwithCustomerLiability	0	USD
CY2018Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	71941000	USD
CY2019Q2	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	58809000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	202000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	31000	USD
CY2018Q2	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	467000	USD
	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	1084000	USD
CY2019Q2	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	398000	USD
	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	1409000	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9114000	USD
CY2019Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	8491000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2701000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7174000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9114000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8491000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1366000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3366000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3357000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2982000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2707000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	189929000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	192956000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1360000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2364000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1452000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2742000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3374000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3374000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21600000	shares
CY2018Q4	us-gaap	Assets Assets	141341000	USD
CY2019Q2	us-gaap	Assets Assets	130840000	USD
CY2019Q1	us-gaap	Assets Assets	143177000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	135382000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	111462000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	18000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	64000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44828000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54901000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44782000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74867000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	99700000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37878000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50576000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74867000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54901000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12698000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19966000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54151219	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49261517	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54151219	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49261517	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3196000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6796000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12409000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21831000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	35612000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28406000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	53303000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	58110000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	56780000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2400000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6500000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-1641000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-100000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
	us-gaap	Depreciation Depreciation	275000	USD
	us-gaap	Depreciation Depreciation	208000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-825000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2001000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2380000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1779000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4779000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9131000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4189000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9121000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-351000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9065000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11758000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22106000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-148000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-148000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-28584000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	7122000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-588000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	662000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	987000	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	449000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	955000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	101406000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	111355000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	104883000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141341000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	130840000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143177000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48076000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	40928000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48228000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	280000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57056000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7596000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	22351000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25841000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-203000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8917000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-11758000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22106000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	13934000	USD
	us-gaap	Operating Expenses OperatingExpenses	26222000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	17562000	USD
	us-gaap	Operating Expenses OperatingExpenses	36790000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2243000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10379000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12230000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22913000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	945000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1068000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	910000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11490000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2030000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2134000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1602000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-237000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	3000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	100000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	100000	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12317000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1266000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	519000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-414000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	272000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2133000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1602000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-237000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1266000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	519000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-414000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	272000	USD
CY2018Q2	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	91000	USD
CY2019Q2	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-54000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	151000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1230000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	327000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-148000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	67222000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	26997000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	808000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1054000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7907	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4574000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4605000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5290000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47207000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	10974000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	35647000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	839000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	97000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	178000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	182000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8415000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7888000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11245000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5049000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	178000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9155000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17091000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13373000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27669000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147066000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170813000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148707000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11224000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14668000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4934000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12468000	USD
CY2018Q2	us-gaap	Revenues Revenues	11691000	USD
	us-gaap	Revenues Revenues	15843000	USD
CY2019Q2	us-gaap	Revenues Revenues	5332000	USD
	us-gaap	Revenues Revenues	13877000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2355000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2742000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	53240000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	44782000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	55000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	181000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	178000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	47207000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	839000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	50692000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	55317000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	39935000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	30162000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	19485000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	38294000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1667000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	93000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53983000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52025000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49204000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50034000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments and accounts receivable. The Company’s cash, cash equivalents and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-19-000051-index-headers.html	Edgar Link	pending
0001583648-19-000051-index.html	Edgar Link	pending
0001583648-19-000051.txt	Edgar Link	pending
0001583648-19-000051-xbrl.zip	Edgar Link	pending
a190531pierissubtenantag.htm	Edgar Link	pending
a190531pierissubtenantag001.jpg	Edgar Link	pending
a190531pierissubtenantag002.jpg	Edgar Link	pending
a190531pierissubtenantag003.jpg	Edgar Link	pending
a190531pierissubtenantag004.jpg	Edgar Link	pending
a190531pierissubtenantag005.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pirs-20190630.xml	Edgar Link	completed
pirs-20190630.xsd	Edgar Link	pending
pirs-20190630_cal.xml	Edgar Link	unprocessable
pirs-20190630_def.xml	Edgar Link	unprocessable
pirs-20190630_lab.xml	Edgar Link	unprocessable
pirs-20190630_pre.xml	Edgar Link	unprocessable
pirs6-30x19ex311.htm	Edgar Link	pending
pirs6-30x19ex312.htm	Edgar Link	pending
pirs6-30x19ex321.htm	Edgar Link	pending
pirs6-30x19ex322.htm	Edgar Link	pending
pirs6-30x201910xq.htm	Edgar Link	pending
pirs_exhibit-101.htm	Edgar Link	pending
pirs_exhibit-101001.jpg	Edgar Link	pending
pirs_exhibit-101002.jpg	Edgar Link	pending
pirs_exhibit-101003.jpg	Edgar Link	pending
pirs_exhibit-101004.jpg	Edgar Link	pending
pirs_exhibit-101005.jpg	Edgar Link	pending
pirs_exhibit-101006.jpg	Edgar Link	pending
pirs_exhibit-101007.jpg	Edgar Link	pending
pirs_exhibit-101008.jpg	Edgar Link	pending
pirs_exhibit-101009.jpg	Edgar Link	pending
pirs_exhibit-101010.jpg	Edgar Link	pending
pirs_exhibit-101011.jpg	Edgar Link	pending
pirs_exhibit-101012.jpg	Edgar Link	pending
pirs_exhibit-101013.jpg	Edgar Link	pending
pirs_exhibit-101014.jpg	Edgar Link	pending
pirs_exhibit-101015.jpg	Edgar Link	pending
pirs_exhibit-101016.jpg	Edgar Link	pending
pirs_exhibit-101017.jpg	Edgar Link	pending
pirs_exhibit-101018.jpg	Edgar Link	pending
pirs_exhibit-101019.jpg	Edgar Link	pending
pirs_exhibit-101020.jpg	Edgar Link	pending
pirs_exhibit-101021.jpg	Edgar Link	pending
pirs_exhibit-101022.jpg	Edgar Link	pending
pirs_exhibit-101023.jpg	Edgar Link	pending
pirs_exhibit-101024.jpg	Edgar Link	pending
pirs_exhibit-101025.jpg	Edgar Link	pending
pirs_exhibit-101026.jpg	Edgar Link	pending
pirs_exhibit-101027.jpg	Edgar Link	pending
pirs_exhibit-101028.jpg	Edgar Link	pending
pirs_exhibit-101029.jpg	Edgar Link	pending
pirs_exhibit-101030.jpg	Edgar Link	pending
pirs_exhibit-101031.jpg	Edgar Link	pending
pirs_exhibit-101032.jpg	Edgar Link	pending
pirs_exhibit-101033.jpg	Edgar Link	pending
pirs_exhibit-101034.jpg	Edgar Link	pending
pirs_exhibit-101035.jpg	Edgar Link	pending
pirs_exhibit-101036.jpg	Edgar Link	pending
pirs_exhibit-101037.jpg	Edgar Link	pending
pirs_exhibit-101038.jpg	Edgar Link	pending
pirs_exhibit-101039.jpg	Edgar Link	pending
pirs_exhibit-102.htm	Edgar Link	pending
pirs_exhibit-102001.jpg	Edgar Link	pending
pirs_exhibit-102002.jpg	Edgar Link	pending
pirs_exhibit-102003.jpg	Edgar Link	pending
pirs_exhibit-102004.jpg	Edgar Link	pending
pirs_exhibit-51.htm	Edgar Link	pending
pirs_exhibit-51001.jpg	Edgar Link	pending
pirs_exhibit-51002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2019 Q3 Form 10-Q Financial Statement

#000158364819000051 Filed on August 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2019 Q3 Form 10-Q Financial Statement

#000158364819000051 Filed on August 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs